文献速递肝病

丙型肝炎病毒相关冷球蛋白血症血管炎患者无干扰素抗病毒治疗方案的长期疗效

Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-05-29

该研究对148例有症状的丙型肝炎病毒相关冷球蛋白血症血管炎(HCV-CryoVas)患者进行前瞻性国际多中心队列随访,患者接受无干扰素直接抗病毒药物(DAA)方案治疗12或24周,中位随访15.3个月。停药12周时完全临床反应72.6%、部分反应22.6%、无反应4.8%,97.2%获持续病毒学应答,严重CryoVas形式和外周神经病变与无或部分反应相关。

要点

  • 停药12周时完全临床反应106例(72.6%),部分反应33例(22.6%),无反应7例(4.8%)。
  • 97.2%患者获持续病毒学应答,53.1%患者血中冷球蛋白不再检出。
  • 严重CryoVas形式(OR 0.33,95%CI 0.12-0.91,P=.03)和外周神经病变(OR 0.31,95%CI 0.11-0.84,P=.02)与无或部分反应相关。

核心结论

  • 在临床试验数据的长期随访分析中,超过95%的HCV-CryoVas患者对不同DAA治疗方案获得症状完全或部分反应,少于5%提前停药,少于3%死亡,严重CryoVas形式和外周神经病变与DAA治疗无反应相关。

研究设计与样本

  • 前瞻性国际多中心队列研究,纳入148例有症状的HCV-CryoVas患者,其中53.7%有肝硬化、49.3%未接受过DAA治疗。
  • 所有患者接受DAA方案(索非布韦联合达拉他韦 n=53;索非布韦联合利巴韦林 n=51;索非布韦联合雷迪帕韦 n=23;索非布韦联合西美瑞韦 n=18),疗程12或24周,治疗时间为2014年至2017年,中位随访时间15.3个月。

主要发现

  • 停药12周时完全反应106例(72.6%)、部分反应33例(22.6%)、无反应7例(4.8%)。
  • 53.1%患者血中冷球蛋白不再检出,97.2%患者获持续病毒学应答,4.1%患者提前停用DAA。
  • 中位随访15.3个月期间4例(2.8%)死亡。
  • 紫癜清除率97.2%、肾脏受累改善率91.5%、关节痛改善率85.7%、神经病变改善率77.1%、冷球蛋白血症改善率52.2%。
  • 严重CryoVas形式与无或部分反应相关(OR 0.33,95%CI 0.12-0.91,P=.03),外周神经病变与无或部分反应相关(OR 0.31,95%CI 0.11-0.84,P=.02)。

关键数值与推荐

  • 完全临床反应定义为基线所有受累器官改善且无临床复发;部分反应定义为基线部分但非全部受累器官改善。
  • 主要终点为停用DAA治疗后第12周时CryoVas症状的临床反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In small-size and short-term studies of hepatitis C virus-associated cryoglobulinemia vasculitis (HCV-CryoVas), patients had a higher rate of response and tolerance to direct-acting antiviral (DAA) agents than interferon-containing regimens. We collected follow-up data from a clinical trial to determine the long-term effectiveness and tolerance of all-oral, interferon-free DAA regimens in patients with CryoVas. METHODS: We collected follow-up data from a prospective international multicenter cohort study of 148 patients with symptomatic HCV-CryoVas (53.7% with cirrhosis and 49.3% naive to treatment with DAAs). All patients received DAA (sofosbuvir plus daclatasvir, n = 53; sofosbuvir plus ribavirin, n = 51; sofosbuvir plus ledipasvir, n = 23; or sofosbuvir plus simeprevir, n = 18), for 12 or 24 weeks, from 2014 through 2017; the median follow-up time was 15.3 months. A complete clinical response was defined as improvement of all organs involved at baseline and the absence of clinical relapse; a partial response was defined as improvement in some but not all organs involved at baseline. The primary end point was clinical response of CryoVas symptoms at week 12 after stopping DAA therapy. RESULTS: A complete response was reported for 106 patients (72.6%), a partial response for 33 patients (22.6%), and no response for 7 patients (4.8%). Cryoglobulins were no longer detected in blood samples from 53.1% of patients, and 97.2% of the patients had a sustained virologic response to therapy. Premature DAA withdrawal was reported for 4.1% of patients. Factors associated with no or partial response to therapy included a severe form of CryoVas (odds ratio, 0.33; 95% CI, 0.12-0.91; P = .03) and peripheral neuropathy (odds ratio, 0.31; 95% CI, 0.11-0.84; P = .02). After a median follow-up time of 15.3 months, 4 patients (2.8%) died. The CryoVas manifestation of purpura was cleared from 97.2% of patients, renal involvement from 91.5% of patients, arthralgia from 85.7% of patients, neuropathy from 77.1% of patients, and cryoglobulinemia from 52.2%. CONCLUSIONS: In a long-term follow-up analysis of data from a clinical trial, we found that more than 95% of patients with HCV-CryoVas have a full or partial response of symptoms to different DAA treatment regimens. Fewer than 5% of patients stop therapy prematurely and less than 3% die. A severe form of CryoVas and peripheral neuropathy were associated with a lack of response of HCV-CryoVas to DAA therapy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Cacoub P, Si Ahmed SN, Ferfar Y, et al. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. Clin Gastroenterol Hepatol. 2018. PMID: 29857143. doi:10.1016/j.cgh.2018.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。